KABS Laboratories Revenue and Competitors
Estimated Revenue & Valuation
- KABS Laboratories's estimated annual revenue is currently $22.7M per year.
- KABS Laboratories's estimated revenue per employee is $201,000
Employee Data
- KABS Laboratories has 113 Employees.
- KABS Laboratories grew their employee count by 4% last year.
KABS Laboratories's People
Name | Title | Email/Phone |
---|---|---|
1 | Quality System Director | Reveal Email/Phone |
2 | Director IT | Reveal Email/Phone |
3 | Assistant Director Quality Systems | Reveal Email/Phone |
4 | Coordonnatrice de projets | Reveal Email/Phone |
5 | Analyst - R&D | Reveal Email/Phone |
6 | Laboratory Analyst - Calculations | Reveal Email/Phone |
7 | Analytical Instrument Technical Support | Reveal Email/Phone |
8 | Quality System Specialist (Environmental Controls and Measures) | Reveal Email/Phone |
9 | Directrice d'usine | Reveal Email/Phone |
10 | Human Resources Consultant | Reveal Email/Phone |
KABS Laboratories Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 9353 | 5% | N/A | N/A |
What Is KABS Laboratories?
Since 1997, KABS has offered a broad range of product development services to the bio-pharmaceutical industry, worldwide. We support pharmaceutical development programs from initial discovery to phase III. Our cGMP compliant services include strategic planning, pre-clinical development, analytical testing, formulation development, manufacturing of prototypes and clinical supplies, distribution of clinical supplies to clinical sites and CMC aspects of regulatory affairs.
keywords:N/AN/A
Total Funding
113
Number of Employees
$22.7M
Revenue (est)
4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $25.4M | 154 | N/A | N/A |
#2 | $52M | 175 | 7% | N/A |
#3 | $37.2M | 185 | 5% | N/A |
#4 | $116.9M | 380 | N/A | N/A |
#5 | $345M | 800 | 9% | N/A |